Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn's Disease.

Bertin L, Barberio B, Gubbiotti A, Bertani L, Costa F, Ceccarelli L, Visaggi P, Bodini G, Pasta A, Sablich R, Urbano MT, Ferronato A, Buda A, De Bona M, Del Corso G, Massano A, Angriman I, Scarpa M, Zingone F, Savarino EV

Open source

DOI
10.3390/jcm13061539
Published
2024 Mar 7
Container
Journal of clinical medicine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/jcm13061539,
  title = {Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn's Disease.},
  author = {Bertin L and Barberio B and Gubbiotti A and Bertani L and Costa F and Ceccarelli L and Visaggi P and Bodini G and Pasta A and Sablich R and Urbano MT and Ferronato A and Buda A and De Bona M and Del Corso G and Massano A and Angriman I and Scarpa M and Zingone F and Savarino EV},
  year = {2024},
  journal = {Journal of clinical medicine},
  doi = {10.3390/jcm13061539},
  url = {https://doi.org/10.3390/jcm13061539}
}

RIS

TY  - JOUR
TI  - Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn's Disease.
AU  - Bertin L
AU  - Barberio B
AU  - Gubbiotti A
AU  - Bertani L
AU  - Costa F
AU  - Ceccarelli L
AU  - Visaggi P
AU  - Bodini G
AU  - Pasta A
AU  - Sablich R
AU  - Urbano MT
AU  - Ferronato A
AU  - Buda A
AU  - De Bona M
AU  - Del Corso G
AU  - Massano A
AU  - Angriman I
AU  - Scarpa M
AU  - Zingone F
AU  - Savarino EV
PY  - 2024
JO  - Journal of clinical medicine
DO  - 10.3390/jcm13061539
UR  - https://doi.org/10.3390/jcm13061539
ER  - 

APA

L, B., B, B., A, G., L, B., F, C., L, C., P, V., G, B., A, P., R, S., MT, U., A, F., A, B., M, D. B., G, D. C., A, M., I, A., M, S., F, Z., & EV, S. (2024). Association between Ustekinumab Trough Levels, Serum IL-22, and Oncostatin M Levels and Clinical and Biochemical Outcomes in Patients with Crohn's Disease.. Journal of clinical medicine. https://doi.org/10.3390/jcm13061539

Source records